Outcomes of re-irradiation for oral cavity squamous cell carcinoma

被引:6
|
作者
Chen, Yen -Chao [1 ]
Fan, Kang-Hsing [2 ,3 ,7 ]
Lin, Chien -Yu [3 ,7 ]
Kang, Chung-Jan [4 ,7 ]
Huang, Shiang-Fu [4 ,7 ]
Wang, Hung-Ming [5 ,7 ]
Cheng, Ann -Joy [3 ,6 ,7 ]
Chang, Joseph Tung-Chieh [3 ,7 ]
机构
[1] Chang Gung Mem Hosp Keelung, Dept Radiat Oncol, Keelung, Taiwan
[2] New Taipei Municipal TuCheng Hosp, Dept Radiat Oncol, New Taipei, Taiwan
[3] Chang Gung Mem Hosp LinKou, Dept Radiat Oncol, 5 Fusing St, Taoyuan 333, Taiwan
[4] Chang Gung Mem Hosp LinKou, Dept Otorhinolaryngol, Taoyuan, Taiwan
[5] Chang Gung Mem Hosp LinKou, Dept Med Oncol, Taoyuan, Taiwan
[6] Chang Gung Univ, Coll Med, Dept Med Biotechnol & Lab Sci, Taoyuan, Taiwan
[7] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
关键词
Head and neck cancer; Oral cavity cancer; Squamous cell carcinoma; Re-irradiation; INTENSITY-MODULATED RADIOTHERAPY; LOCALLY ADVANCED HEAD; CONCURRENT CHEMOTHERAPY; RECURRENT HEAD; SALVAGE REIRRADIATION; PROGNOSTIC-FACTORS; NECK CANCERS; PHASE-II; TRIAL; COMBINATION;
D O I
10.1016/j.bj.2021.12.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: To predict the outcome of reirradiation (re-RT) for oral cavity squamous cell carcinoma (OSCC).Methods: Eighty-three patients met the criterion of having previously irradiated OSCC treated via curative intent re-RT for recurrent or new primary OSCC. The exclusion criteria were a suboptimal dose (<45 Gy) for the first RT and palliative intent for the second irra-diation. Re-RT was defined as at least 75% volume at second RT after receiving at least 45 Gy at the first RT.Results: The 2-year locoregional progression-free survival (LRPFS) and overall survival (OS) rates were 20% and 28%. For LRPFS, four predictors were noted through univariate ana-lyses: performance status (PS) (p = 0.001), a dose of at least 60 Gy (p = 0.001), stage IVB (p = 0.020), and surgery before re-RT (p = 0.041). In multivariate analyses, only PS (p = 0.005) and a dose of at least 60 Gy (p = 0.001) remained significant. For OS, PS (p = 0.001) and a dose of at least 60 Gy (p = 0.042) were still independently associated predictors, but surgery before re-RT became marginally beneficial (p = 0.053). For patients with a poor PS (ECOG = 2-3), the 2-year OS was only 4.5%. Twenty-nine percent of the patients experienced severe late complications (>= Grade 3), and 18% had new episodes of osteoradionecrosis during their follow-up.Conclusion: We identified PS and a re-RT dose >= 60 Gy as predictors for LRPFS and OS. Surgery before re-RT might improve OS. However, the treatment results of re-RT for OSCC were suboptimal. Prospective trials using modern RT techniques, in combination with new therapeutic drugs or radioenhancers, are warranted for improving these dismal outcomes.
引用
收藏
页码:940 / 947
页数:8
相关论文
共 50 条
  • [1] When is re-irradiation in head and neck squamous cell carcinoma not indicated?
    Primož Strojan
    Jonathan J. Beitler
    Carl E. Silver
    William M. Mendenhall
    Ashok R. Shaha
    Alessandra Rinaldo
    Robert P. Takes
    Alfio Ferlito
    European Archives of Oto-Rhino-Laryngology, 2014, 271 : 3107 - 3109
  • [2] When is re-irradiation in head and neck squamous cell carcinoma not indicated?
    Strojan, Primoz
    Beitler, Jonathan J.
    Silver, Carl E.
    Mendenhall, William M.
    Shaha, Ashok R.
    Rinaldo, Alessandra
    Takes, Robert P.
    Ferlito, Alfio
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2014, 271 (12) : 3107 - 3109
  • [3] Outcomes for recurrent oral cavity squamous cell carcinoma
    Contrera, Kevin J.
    Zafereo, Mark E.
    Yaniv, Dan
    Roberts, Diane B.
    Gillenwater, Ann M.
    Hanna, Ehab Y.
    Weber, Randal S.
    Myers, Jeffrey N.
    Chang, Edward I.
    Garvey, Patrick B.
    Hanasono, Matthew M.
    Yu, Peirong
    Hutcheson, Katherine A.
    Fuller, Clifton D.
    Tyler, Matthew A.
    Neskey, David M.
    ORAL ONCOLOGY, 2022, 134
  • [4] Re-irradiation with Cetuximab in relapsed squamous cell carcinoma of the head and neck (HNC)
    Colantonio, I.
    Russi, E.
    Numico, G.
    Cipolat, M.
    Mattiot, V. Polla
    Vitiello, R.
    Merlano, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 492 - 493
  • [5] RE-IRRADIATION OF RECURRENT AND/OR PERSISTENT SQUAMOUS CELL CARCINOMA OF HEAD AND NECK REGION
    Singh, K.
    Shekhar, S.
    Baruah, J. D.
    Bahadur, A. K.
    Gulati, A.
    Rathi, A. K.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S333 - S333
  • [6] Outcomes of oral cavity squamous cell carcinoma in pediatric patients
    Morris, Luc G. T.
    Ganly, Ian
    ORAL ONCOLOGY, 2010, 46 (04) : 292 - 296
  • [7] Outcomes of Young Patients With Oral Cavity Squamous Cell Carcinoma
    Shah, J. L.
    Bui, T.
    Kaplan, M.
    Colevas, A. D.
    Le, Q. T.
    Hara, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S214 - S214
  • [8] INTERSTITIAL IRRADIATION FOR SQUAMOUS CARCINOMA OF THE ORAL CAVITY
    MEIKLE, D
    HIBBERT, J
    WINTER, PJ
    TONG, D
    SHAHEEN, OH
    CLINICAL OTOLARYNGOLOGY, 1985, 10 (04) : 171 - 176
  • [9] Dose intense re-irradiation and chemotherapy for recurrent head and neck squamous cell carcinoma
    Salama
    Vokes, EE
    Milano, MT
    Stenson, K
    Witt, M
    Chmura, SJ
    Haraf, DJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S490 - S491
  • [10] Survival Outcomes of Re-irradiation With Intensity Modulated Radiation Therapy (IMRT) for Recurrent Head and Neck Squamous Cell Carcinoma
    Aguirre, M. T.
    Knackstedt, R.
    Garrett-Mayer, E.
    Sharma, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S468 - S469